
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a strong and well-established biopharmaceutical company with a diverse portfolio of drugs in various therapeutic areas, including HIV, hepatitis, and oncology. The company's recent acquisition of Pharmasset has expanded its presence in the hepatitis C market, and its latest HIV drug, Yeztugo, has been well-received. With a strong pipeline and strategic partnerships, Gilead is positioned for continued growth and has a solid history of managing patent cliffs. However, competition and pricing pressure in the HIV market, as well as ongoing litigation and potential setbacks in pipeline development, may limit short-term upside for the stock. Overall, Gilead offers a mix of stability and potential for growth, making it a Buy-rated stock.
Bears say
Gilead Sciences is facing competition in both its HIV and HCV franchises, potential pricing pressure, and slower than expected uptake of Yescarta. In addition, potential setbacks in its pipeline, particularly in the oncology space, could also impact the stock's performance. This negative outlook is supported by the possibility of downside risks in the company's financials, with a potential DCF valuation scenario of $80 in a worst-case scenario.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares